Drug intelligence / Profile preview

GP-30101

Development stage: Phase 1
Lead developer: Geropharm
Modality: Small Molecules
Administration: Oral

Overview

GP-30101 is an orally administered small molecule drug developed by Geropharm. It acts as an HIV protease inhibitor and is being investigated for the treatment of immune system diseases and infectious diseases, with a primary focus on HIV infection. The drug has reached clinical development stages but does not have FDA approval or designation at this time[1][2][4].

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on GP-30101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GP-30101.

Explore the full profile